Back to Search Start Over

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia.

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia.

Authors :
Anargyrou K
Vaiopoulos G
Terpos E
Tsironi M
Konstantopoulos K
Samarkos M
Meletis J
Source :
Haematologia [Haematologia (Budap)] 2002; Vol. 32 (2), pp. 169-73.
Publication Year :
2002

Abstract

We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not significant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option.

Details

Language :
English
ISSN :
0017-6559
Volume :
32
Issue :
2
Database :
MEDLINE
Journal :
Haematologia
Publication Type :
Academic Journal
Accession number :
12412738
Full Text :
https://doi.org/10.1163/156855902320388023